Tags

Type your tag names separated by a space and hit enter

The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride.
J Am Acad Dermatol. 2006 Dec; 55(6):1014-23.JA

Abstract

BACKGROUND

Male pattern hair loss (MPHL) is a potentially reversible condition in which dihydrotestosterone is an important etiologic factor.

OBJECTIVE

Our aim was to evaluate the efficacy of the type 1 and 2 5alpha-reductase inhibitor dutasteride in men with MPHL.

METHODS

Four hundred sixteen men, 21 to 45 years old, were randomized to receive dutasteride 0.05, 0.1, 0.5 or 2.5 mg, finasteride 5 mg, or placebo daily for 24 weeks.

RESULTS

Dutasteride increased target area hair count versus placebo in a dose-dependent fashion and dutasteride 2.5 mg was superior to finasteride at 12 and 24 weeks. Expert panel photographic review and investigator assessment of hair growth confirmed these results. Scalp and serum dihydrotestosterone levels decreased, and testosterone levels increased, in a dose-dependent fashion with dutasteride.

LIMITATIONS

The study was limited to 24 weeks.

CONCLUSION

Dutasteride increases scalp hair growth in men with MPHL. Type 1 and type 2 5alpha-reductase may be important in the pathogenesis and treatment of MPHL.

Links

Publisher Full Text
Aggregator Full Text

Authors+Show Affiliations

Olsen EA
Duke University Medical Center, Durham, North Carolina, USA. olsen001@mc.duke.edu
Hordinsky M
No affiliation info available
Whiting D
No affiliation info available
Stough D
No affiliation info available
Hobbs S
No affiliation info available
Ellis ML
No affiliation info available
Wilson T
No affiliation info available
Rittmaster RS
No affiliation info available
Dutasteride Alopecia Research Team
No affiliation info available

MeSH

5-alpha Reductase InhibitorsAdultAlopeciaAndrogen AntagonistsAzasteroidsDihydrotestosteroneDose-Response Relationship, DrugDutasterideFinasterideHairHumansIsoenzymesLibidoMaleMiddle AgedScalpTestosteroneTreatment Outcome

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17110217

Citation

Olsen, Elise A., et al. "The Importance of Dual 5alpha-reductase Inhibition in the Treatment of Male Pattern Hair Loss: Results of a Randomized Placebo-controlled Study of Dutasteride Versus Finasteride." Journal of the American Academy of Dermatology, vol. 55, no. 6, 2006, pp. 1014-23.
Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006;55(6):1014-23.
Olsen, E. A., Hordinsky, M., Whiting, D., Stough, D., Hobbs, S., Ellis, M. L., Wilson, T., & Rittmaster, R. S. (2006). The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. Journal of the American Academy of Dermatology, 55(6), 1014-23.
Olsen EA, et al. The Importance of Dual 5alpha-reductase Inhibition in the Treatment of Male Pattern Hair Loss: Results of a Randomized Placebo-controlled Study of Dutasteride Versus Finasteride. J Am Acad Dermatol. 2006;55(6):1014-23. PubMed PMID: 17110217.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. AU - Olsen,Elise A, AU - Hordinsky,Maria, AU - Whiting,David, AU - Stough,Dow, AU - Hobbs,Stuart, AU - Ellis,Melissa L, AU - Wilson,Timothy, AU - Rittmaster,Roger S, AU - ,, PY - 2006/02/07/received PY - 2006/03/29/revised PY - 2006/05/05/accepted PY - 2006/11/18/pubmed PY - 2006/12/9/medline PY - 2006/11/18/entrez SP - 1014 EP - 23 JF - Journal of the American Academy of Dermatology JO - J Am Acad Dermatol VL - 55 IS - 6 N2 - BACKGROUND: Male pattern hair loss (MPHL) is a potentially reversible condition in which dihydrotestosterone is an important etiologic factor. OBJECTIVE: Our aim was to evaluate the efficacy of the type 1 and 2 5alpha-reductase inhibitor dutasteride in men with MPHL. METHODS: Four hundred sixteen men, 21 to 45 years old, were randomized to receive dutasteride 0.05, 0.1, 0.5 or 2.5 mg, finasteride 5 mg, or placebo daily for 24 weeks. RESULTS: Dutasteride increased target area hair count versus placebo in a dose-dependent fashion and dutasteride 2.5 mg was superior to finasteride at 12 and 24 weeks. Expert panel photographic review and investigator assessment of hair growth confirmed these results. Scalp and serum dihydrotestosterone levels decreased, and testosterone levels increased, in a dose-dependent fashion with dutasteride. LIMITATIONS: The study was limited to 24 weeks. CONCLUSION: Dutasteride increases scalp hair growth in men with MPHL. Type 1 and type 2 5alpha-reductase may be important in the pathogenesis and treatment of MPHL. SN - 1097-6787 UR - https://www.unboundmedicine.com/medline/citation/17110217/The_importance_of_dual_5alpha_reductase_inhibition_in_the_treatment_of_male_pattern_hair_loss:_results_of_a_randomized_placebo_controlled_study_of_dutasteride_versus_finasteride_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0190-9622(06)01287-4 DB - PRIME DP - Unbound Medicine ER -